Experienced in Methicillin-Resistant Staphylococcus Aureus (MRSA)

Dr. Pablo Tebas

Infectious Disease
Penn Medicine
MacGregor Infection Medicine And Travel Program
3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
35 Years of Experience

Experienced in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Penn Medicine
MacGregor Infection Medicine And Travel Program
3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pablo Tebas is an Infectious Disease provider in Philadelphia, Pennsylvania. Dr. Tebas has been practicing medicine for over 35 years and is rated as an Experienced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are HIV/AIDS, Nontuberculous Mycobacterial Lung Disease, Myelitis, and AIDS Dysmorphic Syndrome. Dr. Tebas is currently accepting new patients.

His clinical research consists of co-authoring 157 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Universidad Autonoma De Madrid
Residency
Barnes-Jewish Hospital - Washington University, St. Louis
Specialties
Infectious Disease
Licenses
Internal Medicine in PA
Board Certifications
Infectious Disease, 2005
Internal Medicine, 2004
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

MacGregor Infection Medicine and Travel Program
3400 Civic Center Boulevard, South Pavilion, 4th Floor, Philadelphia, PA 19104
Call: 800-789-7366

Additional Areas of Focus

Dr. Tebas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Flu
Aspergillosis
Monkeypox
Meningitis
Cellulitis
Encephalitis
Pulmonary Tuberculosis
Shingles
Blastomycosis
Methicillin-Resistant Staphylococcus Aureus (MRSA)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses
Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Enrollment Status: Terminated
Publish Date: December 20, 2023
Intervention Type: Drug, Device
Study Drug: INO-4800
Study Phase: Phase 2/Phase 3
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Enrollment Status: Completed
Publish Date: December 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)
Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)
Enrollment Status: Unknown
Publish Date: June 25, 2021
Intervention Type: Drug
Study Drugs: Pegylated Interferon alpha 2b (peg-IFN-?2b), 3BNC117 + 10-1074
Study Phase: Phase 1
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Enrollment Status: Completed
Publish Date: April 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
Towards Eradication: Reducing Proviral HIV DNA With Interferon-a Immunotherapy
Towards Eradication: Reducing Proviral HIV DNA With Interferon-a Immunotherapy
Enrollment Status: Unknown
Publish Date: April 05, 2018
Intervention Type: Drug
Study Drug: Peg-IFN-?2b
Study Phase: Phase 2
View 12 Less Clinical Trials

157 Total Publications

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: July 17, 2025
View All 157 Publications
Similar Doctors
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Joseph Kim
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Joseph Kim
Infectious Disease

ID Care, PA

105 Raider Boulevard, Suite 101, 
Hillsborough, NJ 
 (47.3 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Kim is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Sepsis, COVID-19, Bacterial Gastroenteritis, Methicillin-Resistant Staphylococcus Aureus (MRSA), and Prostatectomy.

Ebbing G. Lautenbach
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Ebbing G. Lautenbach
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Ebbing G. Lautenbach
Infectious Disease

University Of Penn - Medical Group

3550 Market St, Fl 2, 
Philadelphia, PA 
 (0.6 miles away)
215-662-9908
Languages Spoken:
English
See accepted insurances

Ebbing Lautenbach is an Infectious Disease provider in Philadelphia, Pennsylvania. Dr. Lautenbach is rated as an Advanced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, Asymptomatic Bacteriuria, Pneumonia, and Gastrostomy.

Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Stephen Williams
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Stephen Williams
Infectious Disease

ID Care, PA

105 Raider Boulevard, Suite 101, 
Hillsborough, NJ 
 (47.3 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Williams is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Williams is rated as a Distinguished provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Sepsis, Cellulitis, Lymphangitis, and Infective Endocarditis.

VIEW MORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tebas's expertise for a condition
ConditionClose
  • Elite
  • HIV/AIDS
    Dr. Tebas is
    Elite
    . Learn about HIV/AIDS.
    See more HIV/AIDS experts
  • Distinguished
  • Nontuberculous Mycobacterial Lung Disease
    Dr. Tebas is
    Distinguished
    . Learn about Nontuberculous Mycobacterial Lung Disease.
    See more Nontuberculous Mycobacterial Lung Disease experts
  • Advanced
  • AIDS Dementia Complex
    Dr. Tebas is
    Advanced
    . Learn about AIDS Dementia Complex.
    See more AIDS Dementia Complex experts
  • AIDS Dysmorphic Syndrome
    Dr. Tebas is
    Advanced
    . Learn about AIDS Dysmorphic Syndrome.
    See more AIDS Dysmorphic Syndrome experts
  • H1N1 Influenza
    Dr. Tebas is
    Advanced
    . Learn about H1N1 Influenza.
    See more H1N1 Influenza experts
  • Hepatitis
    Dr. Tebas is
    Advanced
    . Learn about Hepatitis.
    See more Hepatitis experts
  • Hepatitis C
    Dr. Tebas is
    Advanced
    . Learn about Hepatitis C.
    See more Hepatitis C experts
  • Myelitis
    Dr. Tebas is
    Advanced
    . Learn about Myelitis.
    See more Myelitis experts
View All 9 Advanced Conditions
  • Experienced
  • Aspergillosis
    Dr. Tebas is
    Experienced
    . Learn about Aspergillosis.
    See more Aspergillosis experts
  • COVID-19
    Dr. Tebas is
    Experienced
    . Learn about COVID-19.
    See more COVID-19 experts
  • Cytomegalic Inclusion Disease
    Dr. Tebas is
    Experienced
    . Learn about Cytomegalic Inclusion Disease.
    See more Cytomegalic Inclusion Disease experts
  • Cytomegalovirus Infection
    Dr. Tebas is
    Experienced
    . Learn about Cytomegalovirus Infection.
    See more Cytomegalovirus Infection experts
  • Ebola Virus Disease
    Dr. Tebas is
    Experienced
    . Learn about Ebola Virus Disease.
    See more Ebola Virus Disease experts
  • Encephalitis
    Dr. Tebas is
    Experienced
    . Learn about Encephalitis.
    See more Encephalitis experts
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Close
      0 / 1000

      Please provide us with the below insurance information:

              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.